WegovyCoverage & appeals · GLP-1 receptor agonist

Wegovy denial: how to appeal a semaglutide weight-management denial

Wegovy's denials split cleanly: if the plan covers weight-loss drugs, most denials are about BMI or step-therapy criteria you can document. If the plan excludes them, the cardiovascular indication may be the only door left open.

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults and adolescents who meet BMI criteria, and to reduce cardiovascular risk in adults with established cardiovascular disease who are overweight or obese. Whether a denial is winnable depends on the plan: an unmet-criteria denial is often appealable; a contractual weight-loss-drug exclusion usually is not, though the cardiovascular indication can sometimes provide a separately covered path.

How Wegovy is covered

Plans that cover anti-obesity medication typically require a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, plus documented lifestyle intervention and sometimes step therapy. The cardiovascular risk-reduction indication applies to adults with established cardiovascular disease and overweight/obesity and can be a distinct basis for coverage where the weight-loss benefit is excluded.

Why Wegovy claims get denied

  • The plan excludes weight-loss drugs by contract.
  • BMI or a qualifying comorbidity wasn't documented to the threshold.
  • Step therapy or a required lifestyle-intervention period wasn't completed/documented.
  • Prior authorization missing or incomplete.
  • Medicare: prescribed for weight loss, which Part D cannot cover by statute (the CV indication may differ).

Is a Wegovy denial worth appealing?

Sometimes worth appealing

Often winnable when the plan covers weight-loss drugs and the denial is about criteria — document BMI, comorbidities, lifestyle efforts, and any contraindication to a required step. Rarely winnable against a clear contractual exclusion. Where the patient has established cardiovascular disease, appeal on Wegovy's cardiovascular indication, which can be covered even when a weight-loss benefit is not.

How to appeal a Wegovy denial

  1. 1

    Confirm whether weight-loss drugs are a covered benefit

    If excluded, a medical-necessity appeal won't move it — pivot to the CV indication or a formulary exception.

  2. 2

    Document the BMI criteria

    Attach the BMI, qualifying comorbidities, and the lifestyle-intervention history the plan requires.

  3. 3

    Use the cardiovascular indication where it fits

    For a patient with established cardiovascular disease, frame the appeal on CV risk reduction — a separately approved indication that can survive a weight-loss exclusion.

Wegovy — frequently asked

My plan says weight-loss drugs aren't covered — is Wegovy hopeless?
A medical-necessity appeal rarely overturns an exclusion. But if the patient has established cardiovascular disease, Wegovy's CV risk-reduction indication is a separate, sometimes-covered basis worth appealing on.
Wegovy vs. Ozempic for an appeal?
Same drug, different approval. Wegovy is the semaglutide approved for weight management and CV risk; Ozempic is approved for type 2 diabetes. Appeal on whichever approved indication the patient actually has.

Related guides

Ozempic denialZepbound denialGLP-1 weight-loss denials

Sources

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →